GRM5 and fragile X syndrome: However, clinical trials of mGluR5 NAMs in adolescents and adults with Fragile X syndrome have failed to ameliorate behavioral symptoms (Berry-Kravis et al. 2016; Berry-Kravis et al. 2018).